Whalesbook
The GLP-1 drug market is undergoing a major shift as the cost of semaglutide active pharmaceutical ingredient (API) has fallen sharply. This dramatic change, fueled by increased production and patent expirations, is reshaping the industry beyond just making drugs more affordable. It involves intense competition, strategic pricing moves, and highlights vulnerabilities in global drug supply chains.
API Prices Collapse Amidst Generic Surge
The price of semaglutide API, the key ingredient for drugs like Ozempic and Wegovy, has plunged. It once sold for up to $900 per gram but now ranges from $90-$160 for synthetic versions and as low as $50 per gram for recombinant types. This drop is largely due to massive production increases, especially in China, where manufacturers have cut costs. Experts anticipate another 20-30% price decrease in the coming months as more patent expirations boost supplier volume.
Following the March 20, 2026, patent expiry for Novo Nordisk's semaglutide, major Indian drugmakers including Sun Pharmaceuticals, Dr Reddy's Laboratories, Natco Pharma, Zydus Lifesciences, and Eris Lifesciences have rapidly launched their own generic GLP-1 treatments. These generics are entering the market at discounts of 70-90% compared to the original brands, aiming for significant market share. For example, Natco Pharma's early releases offer vials for about $14 per month, while Sun Pharma has competitive weekly options. This influx of generics is set to dramatically improve access and affordability for millions worldwide dealing with diabetes and obesity.
Market Competition and Company Valuations
Novo Nordisk (NVO), the current market leader, is experiencing intense pressure. Its stock has declined significantly this year and over the past 12 months. The company's price-to-earnings (P/E) ratio has dropped to approximately 10.35-11.5, indicating a lower valuation than its past performance and industry peers. In response, Novo Nordisk started cutting prices for Ozempic and Wegovy in India by up to 48% from April 1, 2026, and is considering branded generics like Plosbrio and Poviztra to stay competitive.
Many Indian generic companies appear to be in a strong position. Natco Pharma has a P/E ratio of about 11.82, potentially indicating it's undervalued by its earnings. Zydus Lifesciences trades at a P/E of 19.09, and Dr Reddy's Laboratories at 18.46, which are within typical ranges for the sector. Analysts have a 'Buy' rating on Dr Reddy's, with target prices around ₹1,500–1,600. Sun Pharmaceutical Industries has a higher P/E of 37.33, suggesting it's valued as a growth stock. Eris Lifesciences has the highest P/E at 44.12, reflecting a premium valuation.
The overall GLP-1 market is expected to grow significantly. Forecasts predict the global market will reach $385.4 billion by 2035, expanding at a compound annual growth rate (CAGR) of 15.1%. The development of oral GLP-1 drugs and new triple-agonist molecules is anticipated to drive this expansion, opening up new areas for innovation and premium pricing.
Supply Chain Risks and Market Vulnerabilities
Despite strong market growth forecasts, significant risks remain. Novo Nordisk heavily depends on revenue from Ozempic and Wegovy, making it highly susceptible to price wars and losing market share to generics. The company's recent stock performance, showing substantial year-to-date and annual declines, highlights this concern. While Novo Nordisk is cutting prices, the long-term effect on its profit margins is uncertain. Introducing lower-priced branded generics could also reduce sales of its more expensive products.
The global pharmaceutical supply chain is notably vulnerable, with an over-reliance on China for APIs and key materials. Geopolitical tensions and trade disputes create an unstable situation where input costs can rise unexpectedly, potentially hurting the profits of even efficient API makers. For Indian generic companies, this dependence on Chinese API supplies is a major weakness. While API prices are currently low, any geopolitical instability or trade barriers could quickly raise costs and affect profit margins. Typically, sharp API price drops lead to oversupply and reduced profits for everyone, a path semaglutide appears to be following.
Outlook for GLP-1 Market and Key Players
Analysts forecast continued strong growth for the GLP-1 market. This is driven by rising diagnoses of metabolic diseases, broader medical uses, and new drug types such as oral versions and triple agonists. While this growth benefits the sector overall, increased competition from generics is likely to keep prices down for current single-agonist drugs. Novo Nordisk must innovate and utilize its drug pipeline, especially in triple agonists, to protect its market standing. Generic companies face the challenge of remaining profitable despite falling prices and potential supply chain issues, while adapting to regulatory changes and meeting growing patient demand.